新型前列环素类似物曲前列尼尔  

The new prostacyclin analog treprostinil

作　　者：顾智淳 刘晓琰[1] 沈节艳[2] 蔡宗烨 

机构地区：[1]上海交通大学医学院附属仁济医院药剂科,上海200127 [2]上海交通大学医学院附属仁济医院心内科,上海200127

出　　处：《中国新药杂志》2014年第22期2585-2588,2592,共5页Chinese Journal of New Drugs

摘　　要：肺动脉高压(PAH)是以肺血管阻力增加导致右心衰和死亡的一类进展性和致死性疾病。曲前列尼尔是一个稳定的前列环素类似物,用于治疗PAH。该药的主要药理作用包括舒张肺血管,抑制血小板聚集及平滑肌细胞增生,可通过皮下、静脉、吸入和口服给药。临床研究表明,曲前列尼尔能够改善PAH患者临床症状和活动耐量,提高生活质量。常见的不良反应(AEs)包括头痛、皮肤潮红、颌痛、腹泻等;皮下给药时注射部位反应较常见。本文就曲前列尼尔的药理作用、药动学、临床研究及安全性作一阐述。Pulmonary arterial hypertension （PAH） is a progressive and fatal disease characterized by in- creasing pulmonary vascular resistance leading to right ventricular failure and death. Treprostinil is a stable prosta- cyclin analog approved for the treatment of PAH. The major pharmacological actions of treprostinil include dilatation of the pulmonary vasculature, inhibition of platelet aggregation and inhibition of smooth muscle cell proliferation. Treprostinil can be administrated by subcutaneous, intravenous, inhaled or oral routes. In clinical trials, treprosti- nil has been shown to improve clinical status, exercise capacity and the quality of life. Common side effects of treprostinil therapy include headache, flushing, jaw pain, diarrhea, and infusion site reactions （for subcutaneous in- jection）. In this paper, we summarized the mechanism, pharmacokinetics, clinical trials and safety of treprostinil.

关 键 词：曲前列尼尔 前列环素类似物 肺动脉高压 

分 类 号：R972.4[医药卫生—药品]